# US 2010/0167982 A1 · Barrier integrity in hiv patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167982 A1
- Document ID: US20100167982A1
- Status: Published application
- Kind: A1
- Application number: 12/648,891
- Filed: 2009-12-29
- Published: 2010-07-01
- Earliest claimed: 2004-06-22
- Assignees: N.V. Nutricia
- Inventors: Eric Alexander Franciscus van Tol; Linette Eustachia Maria Willemsen; Marleen Antoinette Koetsier; Christopher Beermann; Bernd Stahl
- Web page: https://patentgrep.com/patent/US20100167982A1

## CPC

- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A23L 33/12: Fatty acids or derivatives thereof
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A method of improving intestinal barrier integrity of a patient infected with human immunodeficiency virus (HIV), said method comprising administering to the patient infected with HIV a nutritional composition comprising:
a. eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 85 wt. % of the total fat content; and
b. galactooligosaccharide and a fructan selected from the group consisting of fructooligosaccharides, inulin and mixtures thereof.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the composition further comprises gamma-linolenic acid (GLA).

### Claim 15 (depends on 13)

The method according to claim 13, wherein the composition comprises at least 10 wt. % of the oligosaccharide having a degree of polymerisation (DP) of 2 to 5 and at least 5 wt. % has a DP of between 10 and 60.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the composition comprises 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises a member selected from the group consisting of hydrolyzed milk protein, vegetable protein and/or amino acids.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the composition has a caloric content of 0.6 to 0.8 kcal/ml; an osmolality of 50 to 500 mOsm/kg; and a viscosity below 50 mPas.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the patient has a CD4+ T-lymphocyte cell count between 200 to 700 cells/μl blood and is not being treated by Highly Active Antiretroviral Therapy.

### Claim 19 (depends on 13)

The method according to claim 13, wherein the composition further comprises:
c. an acidic oligosaccharide, preferably an uronic acid polymer with a degree of polymerization (DP) between 2 and 60.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the composition further comprises GLA.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the composition comprises at least 10 wt. % of the oligosaccharide having a degree of polymerization (DP) of 2 to 5 and at least 5 wt. % has a DP of between 10 and 60.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the composition comprises 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises a member selected from the group consisting of hydrolyzed milk protein, vegetable protein and/or amino acids.

### Claim 23 (depends on 19)

The method according to claim 19, wherein the composition has a caloric content of 0.6 to 0.8 kcal/ml; an osmolality of 50 to 500 mOsm/kg; and a viscosity below 50 mPas.

### Claim 24 (depends on 19)

The method according to claim 19, wherein the patient has a CD4+ T-lymphocyte cell count between 200 to 700 cells/μl blood and is not being treated by Highly Active Antiretroviral Therapy.